Minerva Biotechnologies Company
Minerva Biotechnologies develops cancer immunotherapies and cancer drugs to target 80% of solid tumors and to prevent cancer metastasis.
Technology:
CAR-T therapy, Stem cell therapy
Industry:
PharmTech, Private
Headquarters:
Waltham, Massachusetts, United States
Founded Date:
1999-01-01
Employees Number:
1-10
Funding Status:
Private Equity
Total Funding:
65509789
Estimated Revenue:
$10M to $50M
Last Funding Date:
2022-01-28
Last Funding Type:
Private Equity
Register and Claim Ownership